Steward Partners Investment Advisory, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Steward Partners Investment Advisory, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$11.69 - $15.02 $1,169 - $1,502	100 Added 20.0%	600 $7,000
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $3,450 - $5,423	300 Added 150.0%	500 $6,000
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $1,720 - $2,526	120 Added 150.0%	200 $3,000
Q3 2022 Nov 10, 2022	BUY	$7.06 - $15.52 $564 - $1,241	80 New	80 $1,000
Q2 2021 Aug 13, 2021	SELL	$4.29 - $6.05 $11,154 - $15,730	-2,600 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$3.45 - $4.69 $8,970 - $12,194	2,600 New	2,600 $11,000
Q1 2020 Apr 29, 2020	SELL	$2.61 - $5.21 $6,525 - $13,025	-2,500 Closed	0 $0
Q4 2019 Jan 17, 2020	SELL	$3.67 - $5.7 $7,340 - $11,400	-2,000 Reduced 44.44%	2,500 $9,000
Q3 2019 Oct 30, 2019	BUY	$3.89 - $7.43 $7,780 - $14,860	2,000 Added 80.0%	4,500 $23,000
Q2 2019 Jul 25, 2019	BUY	$2.7 - $6.11 $6,750 - $15,275	2,500 New	2,500 $9,000
Q4 2018 Jan 15, 2019	SELL	$1.92 - $3.62 $4,800 - $9,050	-2,500 Closed	0 $0
Q2 2018 Jul 20, 2018	BUY	$2.26 - $3.84 $5,649 - $9,600	2,500 New	2,500 $8,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.